Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
. 2011 Dec 6;105(12):1818-24.
doi: 10.1038/bjc.2011.455. Epub 2011 Nov 1.

Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers

E-I Braicu  1 , J Sehouli, R Richter, K Pietzner, C Denkert, C Fotopoulou
Affiliations

Role of histological type on surgical outcome and survival following radical primary tumour debulking of epithelial ovarian, fallopian tube and peritoneal cancers

E-I Braicu et al. Br J Cancer. .

Abstract

Background: To assess the clinical impact of the two histological types as designated in the proposed model for ovarian tumourigenesis in primary epithelial ovarian, fallopian tube or peritoneal cancer (EOC) patients.

Methods: All consecutive EOC patients (n=632) after primary tumour debulking in our institution (09/2000-08/2010) were classified into one of two groups: type I tumours (n=100; 15.8%) composed of low-grade serous, low-grade endometrioid, clear cell, mucinous and transitional carcinomas; and Type II tumours (n=532; 84.1%) composed of high-grade serous, high-grade endometrioid, undifferentiated and malignant mixed-mesodermal tumours. Kaplan-Meier and logistic/Cox-regression analyses were performed to assess the impact of histological type on surgical outcome and survival.

Results: Type II patients had a significantly higher incidence of advanced disease (FIGO III/IV) than Type I patients (79.8% vs 38%, respectively; P<0.001). Median CA125 values (438 vs 93 U ml(-1); P=0.001); operative time (258 vs 237 min; P=0.001); and incidence of incomplete tumour resection (34.4% vs 15%; P<0.001) were significantly higher in patients with Type II. During a mean follow-up time of 23 months (range: 1-106), 17% of patients with type I vs 34.8% of patients with type II tumours relapsed and/or died (P<0.001). Overall survival (P=0.021) and progression-free survival (P=0.003) were also significantly higher in patients with type I tumours. Multivariate analysis, while identifying postoperative tumour residuals, positive lymph nodes and extrapelvic dissemination as independent predictors of survival, failed to demonstrate any prognostic significance of histological type.

Conclusion: Type I EOC patients appear to present at earlier stages have significantly higher survival and more optimal surgical outcome compared with type II patients. However, in advanced stages, histology loses significance as an independent prognosticator.

PubMed Disclaimer

Conflict of interest statement

The authors declare no conflict of interest.

Figures

Figure 1
Figure 1
Tumour dissemination patterns in type I vs type II primary ovarian cancer (OC), according to the ‘Intraoperative Mapping of Ovarian Cancer’ documentation tool and survival curves according to histology depicted separately for FIGO (International Federation of Gynecology and Obstetrics) stages I/II and III/IV.
See this image and copyright information in PMC

References

    1. Bamias A, Psaltopoulou T, Sotiropoulou M, Haidopoulos D, Lianos E, Bournakis E, Papadimitriou C, Rodolakis A, Vlahos G, Dimopoulos MA (2010) Mucinous but not clear cell histology is associated with inferior survival in patients with advanced stage ovarian carcinoma treated with platinum-paclitaxel chemotherapy. Cancer 116(6): 1462–1468 - PubMed
    1. Bell DA (2005) Origins and molecular pathology of ovarian cancer. Mod Pathol 18(Suppl 2): 19–32 - PubMed
    1. Blagden S, Gabra H (2008) Future directions in the management of epithelial ovarian cancer. Future Oncol 4: 403–411 - PubMed
    1. Blagden S, Gabra H (2009) Promising molecular targets in ovarian cancer. Curr Opin Oncol 21(5): 412–419 - PubMed
    1. Eltabbakha GH, Mountb SL, Beattyb B, Simmons-Arnoldb L, Cooperb K, Morgan A (2004) Factors associated with cytoreducibility among women with ovarian carcinoma. Gynecol Oncol 95: 377–383 - PubMed